For decades, innovation in the vapor industry has focused on improving how nicotine is delivered. 

We’ve seen better devices, new formulations, nicotine salts, pouches and entirely new product categories. But through all of that innovation, one thing has largely stayed the same: 

Nicotine itself. 

Nixodine is challenging that idea. 

A newly published study in Toxicology Reports takes a closer look at Nixodine-S, a patented formulation containing (S)-6-methylnicotine, and the results point to an exciting new direction for adult-use nicotine alternatives. 

The research found that Nixodine-S maintained nicotine-like activity at key receptors associated with nicotine-related satisfaction while producing similar or better results than nicotine across the in vitro toxicology tests conducted.  

For an industry that has spent years innovating around nicotine, this raises a much bigger possibility: 

What if the next generation of alternatives moves beyond nicotine altogether? 

 

What Is Nixodine-S? 

Nixodine-S is a patented, flavorless concentrate containing (S)-6-methylnicotine, or (S)-6-MN. 

Unlike conventional nicotine, Nixodine-S is not tobacco-derived and is chemically distinct from nicotine. It has been formulated as a volume-for-volume alternative to nicotine for use in manufacturing adult vapor and oral products.  

That could be significant for manufacturers. 

Rather than requiring companies to completely reinvent their manufacturing processes, Nixodine-S was developed as a substitution platform that can potentially be incorporated into existing production systems.  

But the bigger question has always been: How does it actually compare with nicotine? 

That's what this new research begins to answer. 

 

The Study Put Nixodine-S Head-to-Head With Nicotine 

Researchers compared pure Nixodine-S with pure nicotine across standardized in vitro testing that looked at: 

• Cell viability and cytotoxicity  

• Genotoxicity  

• Mutagenicity  

• Activation of three human nicotinic acetylcholine receptor subtypes  

The receptor testing was conducted at Charles River Discovery, while the toxicology testing was conducted at McKinney Specialty Labs using internationally recognized OECD testing frameworks.  

And the results are worth paying attention to. 

 

Nixodine-S Produced a Markedly More Favorable Cytotoxicity Result 

One of the biggest findings involved cytotoxicity. 

In the neutral red uptake assay, nicotine had a measured IC50 of 961.8 µg/mL. 

Nixodine-S, meanwhile, did not induce cytotoxicity through concentrations equivalent to 2,000 µg/mL of nicotine under the volume-equivalent conditions tested.  

In addition, both Nixodine-S and nicotine tested negative for genotoxicity in the in vitro micronucleus assay and negative for mutagenicity in the Ames bacterial reverse-mutation assay across five bacterial strains.  

Taken together, the results give researchers a strong reason to continue investigating Nixodine-S and its potential as an alternative to conventional nicotine. 

 

The Receptor Results Are Just as Interesting 

The other major part of the study looked at how Nixodine-S interacts with human nicotinic acetylcholine receptors. 

Researchers studied three receptor subtypes: α4β2, α3β4 and α6/3β2β3. 

At the α4β2 and α3β4 receptors, Nixodine-S demonstrated activity broadly comparable to nicotine. In this study, Nixodine-S was actually slightly more potent at those two receptors, although the researchers noted that the differences were small and unlikely to be statistically significant.  

Why does that matter? 

These receptor pathways are associated with nicotine reinforcement and the satisfaction adult nicotine users recognize from a product. 

In other words, the early research suggests it may be possible to change the underlying molecule without completely losing the receptor-level activity associated with the familiar nicotine experience. 

That's a pretty significant concept for this industry. 

 

This Is More Than Another New Vape Ingredient 

That's what makes Nixodine particularly interesting to us at Mi-Pod. 

The vapor industry has never lacked innovation. 

We've watched the market move from early open systems to pod systems, nicotine salts, disposables, high-capacity devices, nicotine pouches and countless other developments. 

But almost all of those innovations changed how nicotine was delivered. 

Nixodine is attempting to change the molecule being delivered. 

As Bonguard Naturals CEO and Co-Founder Rick Avila explained when announcing the research, the industry has spent decades innovating around nicotine; Nixodine is focused on innovating beyond it.  

That is a fundamentally different approach. 

 

Mi-Pod Is Already Leading in the Nixodine Category 

At Mi-Pod, we believe it's important to pay attention when genuinely new categories begin emerging. 

That's why Mi-Pod has been an early industry leader in carrying Nixodine products and making them available to our retail and distribution partners. 

We've already seen significant innovation around Nixodine-based products, and this new research adds something incredibly important to that growth: 

science. 

New ingredients shouldn't simply appear on the market without questions being asked about them. They should be tested, studied and characterized. 

That's exactly what we're beginning to see with Nixodine-S. 

The published research gives manufacturers, distributors and retailers new scientific information about how this specific formulation compares with conventional nicotine under controlled laboratory conditions. 

And this is only the beginning. 

 

Could This Be the Beginning of a New Category? 

That's the question we think the industry should be asking. 

The findings don't mean the research is finished. The study is nonclinical, and human clinical trials have not yet been completed. The researchers support continued evaluation of the formulation.  

But every emerging category starts somewhere. 

And this study provides compelling early evidence that a specifically formulated nicotine alternative can maintain activity at important nicotine-associated receptors while demonstrating a differentiated receptor profile and encouraging in vitro toxicology results. 

That's a development worth watching. 

For years, tobacco harm reduction has been about finding better ways to move adult smokers away from combustible cigarettes. 

Vapor changed the delivery system. 

Nicotine salts changed the experience. 

Pouches created another smoke-free category. 

Nixodine may represent something different again: the possibility of moving beyond conventional nicotine itself. 

At Mi-Pod, we're excited to be at the forefront of this emerging category, and we'll continue bringing our partners new Nixodine products as the science, technology and market continue to develop. 

Read the full study here.